Paul Sekhri Net Worth
The estimated Net Worth of Paul J Sekhri is at least $4.16 Million dollars as of 4 October 2019. Mr. Sekhri owns over 628 units of Veeva Systems stock worth over $2,311,595 and over the last 5 years he sold VEEV stock worth over $1,644,867. In addition, he makes $199,947 as Independent Director at Veeva Systems.
Mr. Sekhri VEEV stock SEC Form 4 insider trading
Paul has made over 26 trades of the Veeva Systems stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 628 units of VEEV stock worth $94,828 on 4 October 2019.
The largest trade he’s ever made was exercising 20,000 units of Veeva Systems stock on 3 December 2018 worth over $2,860,000. On average, Paul trades about 2,652 units every 33 days since 2014. As of 4 October 2019 he still owns at least 16,165 units of Veeva Systems stock.
You can see the complete history of Mr. Sekhri stock trades at the bottom of the page.
Paul Sekhri biography
Paul Jai Sekhri is Independent Director of the company. Mr. Sekhri has served as a member of our Board since July 2014. Since February 2016, Mr. Sekhri has been Operating Partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Concurrently and since February 2015, Mr. Sekhri has been President and CEO of Lycera Corp., a biopharmaceutical company. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi S.A., a multinational pharmaceutical company headquartered in France, from April 2014 to January 2015. From May 2013 to March 2014, Mr. Sekhri was Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries, Ltd., a global pharmaceuticals company focusing on the manufacture of generic and proprietary pharmaceutical products headquartered in Israel. From January 2009 to May 2013, Mr. Sekhri was Operating Partner and Head, Biotech Ops Group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG Capital, where he was responsible for a portfolio of more than 50 life sciences companies. From December 2004 to January 2009, Mr. Sekhri was President and CEO of Cerimon Pharmaceuticals, Inc., a pharmaceutical company focusing on auto-immune diseases and pain management. Mr. Sekhri has served as a director of numerous private and public company boards, including Compugen Ltd. since October 2017, Alpine Immune Sciences since July 2017, Pharming N.V. since April 2015, Nivalis Therapeutics, Inc. from February 2016 to July 2017 when it was acquired by Alpine Immune Sciences, Enumeral Biomedical Holdings, Inc. from December 2014, Tandem Diabetes Care Inc. from May 2012 to May 2013, MacroGenics, Inc. from January 2010 to May 2013 and Intercept Pharmaceuticals, Inc. from January 2008 to September 2012.
What is the salary of Paul Sekhri?
As the Independent Director of Veeva Systems, the total compensation of Paul Sekhri at Veeva Systems is $199,947. There are 10 executives at Veeva Systems getting paid more, with Peter Gassner having the highest compensation of $88,143,296.
How old is Paul Sekhri?
Paul Sekhri is 60, he’s been the Independent Director of Veeva Systems since 2014. There are 2 older and 10 younger executives at Veeva Systems. The oldest executive at Veeva Systems, Inc. is Timothy Barabe, 66, who is the Independent Director.
What’s Paul Sekhri’s mailing address?
Paul’s mailing address filed with the SEC is C/O VEEVA SYSTEMS INC., 4280 HACIENDA DRIVE, PLEASANTON, CA, 94588.
Insider trading at Veeva Systems
Over the last 6 years, insiders at Veeva Systems have traded over $1,687,484,451 worth of Veeva Systems stock. The most active insider traders include Gordon Ritter, Capital Partners Ii Lpemerg…, and Kevin Spain. On average, Veeva Systems executives and independent directors trade stock every 3 days with the average trade being worth of $12,613,118. The most recent stock trade was executed by Jonathan Faddis on 28 October 2019, trading 1,166 units of VEEV stock currently worth $171,670.
What does Veeva Systems do?
Veeva Systems, Inc. engages in the provision of industry-specific, cloud-based software solutions for the life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm’s customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage a regulated, content-centric processes across the enterprise. The company’s customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.
What does Veeva Systems’s logo look like?
Complete history of Mr. Sekhri stock trades at Veeva Systems and Alpine Immune Sciences
Veeva Systems executives and stock owners
Veeva Systems executives and other stock owners filed with the SEC include:
- Peter Gassner, Chief Executive Officer, Director
- Jonathan Faddis, Senior Vice President, General Counsel, Corporate Secretary
- Frederic Lequient, Senior Vice President – Global Customer Services
- E. Nitsa Zuppas, Chief Marketing Officer
- Alan Mateo, Executive Vice President of Global Sales
- Gordon Ritter, Independent Chairman of the Board
- Ronald Codd, Independent Director
- Timothy Cabral, Chief Financial Officer
- Paul Chamberlain, Independent Director
- Timothy Barabe, Independent Director
- Paul Sekhri, Independent Director
- Mark Carges, Independent Director
- Rick Lund, Investor Relations Director
- Michele O’Connor, Principal Accounting Officer
- Thomas D. Schwenger, President and COO
- Mary Lynne Hedley, Director
- Matthew J Wallach, President
- Frank Defesche, SVP, Global Customer Services
- Mark Armenante, Director
- Young A Sohn, Director
- Capital Partners Ii Lpemerg…,
- Kevin Spain, Director
- Jenna Mitchell, 10% owner
- Maja Kristin, 10% owner
- James Burr Ramsey, 10% owner
- Craig Ramsey, 10% owner